Galecto Inc Stock News

BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the “Company” or “Galecto”) (Nasdaq: GLTO) today announced that the Company's Board of Directors approved the grant of non-qualified stock options to purchase 312,535 shares of the Company's common stock to one new employee (the “Inducement Grant”) on December 15, 2025 (the “Grant Date”). The Inducement Grant has been granted pursuant to ...

Two obscure US biotech and medtech names – Galecto Inc (NASDAQ: GLTO) and Movano Inc (NASDAQ: MOVE) – stunned markets today with explosive rallies, each surging roughly 300%. While the gains were triggered by company-specific news, the magnitude of the moves has drawn speculative interest from retail traders and momentum chasers.

Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative Neoplasms

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced its operating and financial results for the quarter ended September 30, 2025.

Galecto stock (NASDAQ: GLTO) went absolutely bonkers on Tuesday, surging over 600% in what might be one of the wildest rallies we have seen from a small biotech in recent memory. The shares jumped from a close of $3.71 the day before to an intraday high around $25.99, fueled by a massive pre-market buying spree.

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended June 30, 2025.